Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 14
Submit an article Journal homepage
157
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience

Huw Richardsa Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4844-3498
ORCID Icon,
Selina J. Chavdaa Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK;b Department of Haematology, UCL Cancer Institute, London, UK
,
William Wilsonc Cancer Research UK & UCL Cancer Trials Centre, London, UK
,
Marquita Camilleria Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UKORCID Iconhttps://orcid.org/0000-0002-4161-8275
ORCID Icon,
Oliver Cohena Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK
,
Jackie Hordera Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK
,
Fiona Newricka Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK
,
Xenofon Papanikolaoua Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK
,
Jonathan Sivea Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK
,
Lydia Leea Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK;b Department of Haematology, UCL Cancer Institute, London, UK
,
Rakesh Popata Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK
,
Ashutosh Wechalekara Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK
,
Charalampia Kyriakoua Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK
,
Kwee Yonga Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK;b Department of Haematology, UCL Cancer Institute, London, UK
&
Neil Rabina Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK
 show all
Pages 3544-3547 | Received 19 May 2021, Accepted 20 Jul 2021, Published online: 04 Aug 2021

References

  • Cavo M, Goldschmidt H, Rosinol L, et al. Double Vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: Long-Term follow-up (10-Years) analysis of randomized phase 3 studies. Blood. 2018;132(Supplement 1):124–124.
  • Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–1629.
  • National Institute for Health and Care Excellence (NICE) Recommendations | Myeloma: diagnosis and management. NG35. 2016. [cited 2021 May 19]. Available from https://www.nice.org.uk/guidance/ng35/chapter/recommendations.
  • Giralt S, Garderet L, Durie B, et al. American society of blood and marrow transplantation, European society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and international myeloma working group consensus conference on salvage hematopoietic cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transpl. 2015;21(12):2039–2051.
  • Cook G, Ashcroft AJ, Cairns DA, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF myeloma X relapse [intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3(7):e340–51–e351.
  • Goldschmidt H, Baertsch MA, Schlenzka J, et al.; German Myeloma Multicenter Group (GMMG). Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2021;35(4):1134–1144.
  • Hagen PA, Stiff P. The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma. Biol Blood Marrow Transplant. 2019;25(3):e98–e107.
  • Tremblay D, Lancman G, Moshier E, et al. Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents. Bone Marrow Transplant. 2017;52(10):1468–1470.
  • Chow AWS, Lee CHS, Hiwase DK, et al. Relapsed multiple myeloma: Who benefits from salvage autografts? Intern Med J. 2013;43(2):156–161.
  • Gössi U, Jeker B, Mansouri Taleghani B, et al. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. Hematol Oncol. 2018;36(2):436–444.
  • Lemieux E, Hulin C, Caillot D, et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant. 2013;19(3):445–449.
  • Gonsalves WI, Gertz MA, Lacy MQ, et al. Second auto-SCT for treatment of relapsed multiple myeloma. Vol. 48. Bone Marrow Transplant. 2013;48(4):568–573.
  • Michaelis LC, Saad A, Zhong X, et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013;19(5):760–766.
  • Auner HW, Szydlo R, Rone A, et al. Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma. 2013;54(10):2200–2204.
  • Yhim HY, Kim K, Kim JS, et al.; the Korean Multiple Myeloma Working Party (KMMWP). Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT. Bone Marrow Transplant. 2013;48(3):425–432. 3

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.